Bruker (BRKR) Expected to Announce Earnings on Wednesday

Bruker (NASDAQ:BRKR) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 7th. Analysts expect Bruker to post earnings of $0.44 per share and revenue of $763.83 million for the quarter. Bruker has set its FY 2025 guidance at 2.670-2.720 EPS.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Stock Up 0.5 %

BRKR stock opened at $39.84 on Wednesday. The company has a market capitalization of $6.04 billion, a price-to-earnings ratio of 52.42, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The business’s 50 day moving average price is $42.72 and its two-hundred day moving average price is $52.36. Bruker has a fifty-two week low of $34.10 and a fifty-two week high of $81.07. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date was Monday, March 17th. Bruker’s dividend payout ratio is presently 26.32%.

Wall Street Analyst Weigh In

BRKR has been the topic of several recent analyst reports. Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Barclays dropped their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Wells Fargo & Company lowered their price target on Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. Guggenheim reissued a “buy” rating on shares of Bruker in a report on Monday, February 24th. Finally, Citigroup decreased their price target on shares of Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.